What we're reading, January 15, 2016: new report finds flaws in how the FDA tracks drugs after they reach the market; rate of uninsured Hispanic children hits historic low; and CVS and New York State make medication that reverses opioid overdose available without prescription.
A new report from the Government Accountability Office has found flaws in the way the FDA tracked drugs once they were on the market. Overall, the FDA was not doing a good job with following up with how the drug does in the marketplace with issues such as patients reporting problems taking the drug. The New York Times reported that with one-fourth of drugs approved from October 2006 to December 2014 going through an expedited program, longer-term evidence on a drug’s safety and efficacy is not making it into the public realm.
The rate of uninsured Hispanic children fell to a historic low in 2014 with the rate falling to 9.7%, down 2 percentage points below 2013. According to Kaiser Health News, the improved rate may be a result of Hispanic adults having more opportunities to enroll in health coverage thanks to premium subsidies and expanding Medicaid programs and signing their children up at the same time. However, despite the drop in the rate of Hispanic children without health insurance, they still represent a disproportionate share of the country’s uninsured children.
In New York State, CVS will make naloxone, a medication that reverses opioid overdose, available without a prescription to customers. Traditionally, naloxone is administered by emergency medical or hospital personnel, but can be administered with minimal training, which CVS pharmacists can now provide when they dispense the drug, according to a press release. Access to naloxone had been one of Governor Andrew M. Cuomo’s priorities as part of his plan to address the opioid epidemic in New York.
Real-World Study Reveals Key Insights into DLBCL Treatment Patterns, Outcomes
April 18th 2024A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.
Read More
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Gene, Light Therapy Combo Shows Promise Against Prostate Cancer Cells in Proof-of-Concept Study
April 18th 2024In their preclinical model, the researchers found efficacy both in vitro and in vivo by using CRISPR-Cas9 to mimic porphyria and combining the technology with light therapy.
Read More
Drs Raymond Thertulien, Joseph Mikhael on Racial Disparities in Multiple Myeloma Care Access
December 28th 2023In the wake of the 2023 American Society of Hematology Annual Meeting and Exposition, Raymond Thertulien, MD, PhD, of Novant Health, and Joseph Mikhael, MD, MEd, FRCPC, FACP, chief medical officer of the International Myeloma Foundation, discussed health equity research highlights from the meeting and drivers of racial disparities in multiple myeloma outcomes.
Listen
Collecting SDOH Data Can Assess Risk of Medical Nonadherence, Improve HEI and Star Ratings
April 18th 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, a panel of presenters explored changes coming to Medicare that incorporate social determinants of health (SDOH) data to improve patient and health system outcomes.
Read More